Septerna (SEPN) recently joined several Russell growth and small cap indices. This change can affect how index-tracking and benchmark-aware funds treat the stock and influence overall investor attention.

See our latest analysis for Septerna.

Septerna’s recent Russell index inclusions come after a strong run in the stock, with a 90 day share price return of 55.61% and a 1 year total shareholder return of 206.31%. This comes even though the latest close at $35.93 followed a 1 day share price decline of 5.05%.

If this kind of move has you thinking about where else momentum and fundamentals might line up, it is a good moment to scan the market using our 18 top founder-led companies

Septerna now combines a fast moving share price with a clinical stage pipeline and partnership that many investors see as strengths. The real issue is whether the current valuation still reflects that balance.

Preferred Price-to-Sales Multiple of 22.4x: Is It Justified?

With Septerna closing at $35.93, the current valuation lines up with a P/S ratio of 22.4x, which sits well above several key comparison points.

The P/S ratio compares the company’s market value to its revenue, so a higher multiple usually reflects strong expectations for future progress or a scarce asset in a specialist area. For Septerna, this is being applied to a clinical stage biotechnology business that is currently loss making, with revenue of $72.26m and a reported net loss of $36.04m.

On this measure, the stock trades at a much richer level than peers. Septerna is described as expensive versus its peer average P/S of 3.7x and also versus the wider US Pharmaceuticals industry average of 6.5x. It is also trading well above an estimated fair P/S ratio of 4.3x, which points to a level that the market could move toward if expectations reset closer to sector norms.

Explore the SWS fair ratio for Septerna

Result: Price-to-sales of 22.4x (OVERVALUED)

However, Septerna’s premium P/S, ongoing net loss of $36.04m, and annual declines in revenue and net income growth could challenge sentiment if progress stalls or if expectations cool.

Find out about the key risks to this Septerna narrative.

Next Steps

With sentiment clearly mixed around Septerna’s premium valuation and clinical progress, it makes sense to review the underlying data yourself and act decisively. To see both sides of the story in one place, review the 1 key reward and 2 important warning signs

Looking for more investment ideas beyond Septerna?

Do not stop your research with Septerna. Broaden your watchlist with focused stock ideas so you are ready when the next opportunity lines up with your strategy.

• Spot potential mispriced opportunities early by scanning 44 high quality undervalued stocks that pair strong fundamentals with appealing price tags.
• Strengthen your income stream by reviewing 9 dividend fortresses that aim to combine higher yields with resilient business models.
• Prioritize capital preservation by assessing 76 resilient stocks with low risk scores that score well on financial stability and downside risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.